p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies

Journal of Neurochemistry

Volumn 69, Issue 2, 1997, Pages 780-790

  Hirata, Hiroshi ^a   Cadet, Jean Lud ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Dopamine systems; Dopamine transporter; Methamphetamine; Neurotoxicity; p53; Striatum; Substantia nigra

Indexed keywords

DOPAMINE; MESSENGER RNA; METHAMPHETAMINE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG ABUSE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NERVE ENDING; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PERIKARYON; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0030840777     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69020780.x     Document Type: Article

References (57)

1. Andersen J. K., Frim D. M., Isacson O., Beal M. F., and Breakefield X. O. (1994) Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Res. 656, 108-114.
2. Baldwin H. A., Colado M. I., Murry T. K., De Souza R. J., and Green A. R. (1993) Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br. J. Pharmacol. 108, 590-596.
3. Bloch B., Poporici T., Le Guellec D., Normand E., Chouham S., Guitteny A. F., and Bohlen P. (1986) In situ hybridization histochemistry for the analysis of gene expression in the endocrine and central nervous system tissue: a 3-year experience. J. Neurosci. Res. 16, 183-200.
4. 125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester. Mol. Pharmacol. 47, 779-786.
5. Cadet J. L. (1988) A unifying hypothesis of movement and madness: involvement of free radicals in disorders of the isodendritic core. Med. Hypotheses 27, 87-94.
6. Cadet J. L. and Brannock C. (1997) Invited review: free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. (in press).
7. Cadet J. L., Sheng P., Ali S., Rothman R., Carlson E., and Epstein C. J. (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62, 380-383.
8. Cadet J. L., Landenheim B., Hirata H., and Rothman R. B. (1995) Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse 21, 169-176.
9. Cadet J. L., Ordonez S. V., and Ordonez J. V. (1997) Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2. Synapse 25, 176-184.
10. Cerruti C., Walther D. M., Kuhar M. J., and Uhl G. (1993) Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Mol. Brain Res. 18, 181-186.
11. Clarke A. R., Puride C. A., Harrison D. J., Morris R. G., Bird C. C., Hooper M. L., and Wyllie A. H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathway. Nature 362, 849-852.
12. Cohen G. and Heikkila R. E. (1974) The generation of hydrogen peroxide, superoxide radical and hydroxyl radical by hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 249, 2447-2452.
13. Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695.
14. Crumrine R. C., Thomas A. L., and Morgan P. F. (1994) Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J. Cereb. Blood Flow Metab. 14, 887-891.
15. Cubells J. F., Rayport S., Rajndron G., and Sulzer D. (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14, 2260-2271.
16. De Vito M. J. and Wagner G. C. (1989) Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28, 1145-1150.
17. Donehower L. A. and Bradley A. (1993) The tumor suppressor p53. Biochim. Biophys. Acta 1155, 181-205.
18. Donehower L. A., Harvey M., Siagel B. L., McArthur M. J., Montgomery C. A. Jr., Butel J. S., and Bradley A. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
19. Eisch A. J., Gaffiney M., Weihmuller F. B., O'Dell S. J., and Marshall J. F. (1992) Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res. 598, 321-326.
20. El-Deiry W. S., Harper J. W., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., and Wang Y. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169-1174.
21. Fritsche M., Haessler C., and Brandner G. (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8, 307-318.
22. Giardino L., Ceccatelli S., Zanni M., Hokfelt T., and Calza L. (1994) Regulation of VIP mRNA expression by thyroid hormone in different brain areas of adult rat. Mol. Brain Res. 27, 87-94.
23. Hermeking H. and Eick D. (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265, 2091-2093.
24. Hirata H., Ladenheim B., Carlson E., Epstein C., and Cadet J. L. (1996) Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res. 714, 95-103.
25. Hollstein M., Sidransky D., Vogelstein B., and Harris C. C. (1991) p53 mutations in human cancers. Science 253, 49-53.
26. Hotchkiss A. J. and Gibb J. W. (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther. 214, 257-262.
27. Kastan M. B., Onyewere O., Sidransky D., Vogelstein B., and Craig R. W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
28. Kupsch A., Loschmann P. A., Sauer H., Arnold G., Renner P., Pufal D., Burg M., Wachtel H., Bruggencate G., and Oertel W. H. (1992) Do NMDA receptor antagonists protect against MPTP-toxicity: biochemical and immunocytochemical analysis on black mice. Brain Res. 59, 74-83.
29. Levine A. J., Momand J., and Finlay C. A. (1991) The p53 tumour suppressor gene. Nature 351, 453-456.
30. Lowe S. W., Ruley H. E., Jacks T., and Housman O. E. (1993a) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 1957-1967.
31. Lowe S. W., Schmitt E. M., Smith S. W., Osborne B. A., and Jacks T. (1993b) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849.
32. 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm. Neurosci. Lett. 121, 211-214.
33. Milner J., Chan Y. S., Medcalf E. A., Wang Y., and Eckhart W. (1993) Partially transformed T3T3 cells express high levels of mutant p53 in the 'wild-type' immunoreactive form with defective oligomerization. Oncogene 8, 2001-2008.
34. Miyashita T., Krajewski S., Krajewski M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., and Reed J. C. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805.
35. Morgenbesser S. D., Williams B. O., Jacks T., and Depinho R. A. (1994) p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371, 72-74.
36. Morrison R. S., Wenzel H. J., Kinoshita Y., Robbins C. A., Donehower L. A., and Schwartzkroin P. A. (1996) Loss of p53 tumor suppressor gene protects neurons from kainate-induced cell death. J. Neurosci. 16, 1337-1345.
37. Nash J. F. and Yamamoto B. K. (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581, 237-243.
38. O'Callaghan J. P. and Miller D. E. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741-751.
39. 2 antagonists. J. Neurochem. 60, 1792-1799.
40. O'Dell S. J., Weihmuller F. B., McPherson R. J., and Marshall J. F. (1994) Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions. J. Pharmacol. Exp. Ther. 269, 1319-1325.
41. Oltvai Z. N., Milliman C. L., and Korsmeyer S. J. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619.
42. Ricaurte G. A., Schuster C. R., and Seiden L. S. (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: regional study. Brain Res. 193, 153-163.
43. Sakhi S., Bruce A., Sun N., Tocco G., Baudry M., and Schreiber S. S. (1994) p53 induction is associated with neuronal damage in the central nervous system. Proc. Natl. Acad. Sci. USA 91, 7525-7529.
44. Seiden L. S., Commins D. L., Vosmer G., Axt K., and Marek G. (1988) Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projection. Ann. NY Acad. Sci. 537, 161-172.
45. Selvakumaran M., Lin H. K., Miyashita T., Wang H. G., Krajewski S., Reed J. C., Hoffman B., and Liebermann D. A. (1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9, 1791-1798.
46. Sheng P., Ladenheim B., Moran T. H., Wang X. B., and Cadet J. L. (1996) Methamphetamine-induced neurotoxicity is associated with increased striatal AP-1 DNA-binding activity in mice. Mol. Brain Res. 42, 171-174.
47. Shimada S., Kitayama S., Lin C. L., Patel A., Nanthakumar E., Gregor P., Kuhar M., and Uhl G. (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254, 576-578.
48. Slotnick B. M. and Leonard C. M. (1975) A Stereotaxic Atlas of the Albino Mouse Forebrain. DHEW Publication, Rockville, Maryland.
49. Sonsalla P. K., Nicklas W. J., and Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine-induced dopaminergic toxicity. Science 243, 398-400.
50. Sonsalla P. K., Riordan D. E., and Heikkila R. E. (1991) Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256, 506-512.
51. Steranka L. R. and Sanders-Bush E. (1980) Long-term effects of continuous exposure to amphetamine in brain dopamine concentration and synaptosomal uptake in mice. Eur. J. Pharmacol. 65, 439-443.
52. Wagner A. J., Kokontis J. M., and Hay N. (1994) Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 waf1/cip1. Genes Dev. 8, 2817-2830.
53. Wagner G. C., Ricaurte G. A., Seiden L. S., Schuster C. R., Miller R. J., and Westley J. (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181, 151-160.
54. Wagner G. C., Carelli R. M., and Jarvis M. F. (1985) Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res. Commun. Chem. Pathol. Pharmacol. 47, 221-228.
55. Wood A. K. and Youle R. J. (1995) The role of free radicals and p53 in neuron apoptosis in vivo. J. Neurosci. 15, 5851-5859.
56. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A. and Oren M. (1991) Wild-type p53 induced apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347.
57. Zhan Q., Carrier F., and Fornace A. J. (1993) Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell. Biol. 13, 4242-4250.